Omega Therapeutics (Omega Therapeutics) FCF Yield % : -63.57 (As of May. 11, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Omega Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Omega Therapeutics's Trailing 12-Month Free Cash Flow is $-75.74 Mil, and Market Cap is $108.10 Mil. Therefore, Omega Therapeutics's FCF Yield % for today is -63.57%.

The historical rank and industry rank for Omega Therapeutics's FCF Yield % or its related term are showing as below:

OMGA' s FCF Yield % Range Over the Past 10 Years
Min: -119.63 Med: -36.2 Max: -9.49
Current: -63.57

During the past 5 years, the highest FCF Yield % of Omega Therapeutics was -9.49%. The lowest was -119.63%. And the median was -36.20%.

OMGA's FCF Yield % is ranked worse than
78.92% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs OMGA: -63.57

Omega Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -522.88%.

Omega Therapeutics FCF Yield % Historical Data

The historical data trend for Omega Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omega Therapeutics FCF Yield % Chart

Omega Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-10.91

-36.39

-56.86

Omega Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial													-33.89	-30.15	-77.73	-41.18	-24.52

Competitive Comparison of Omega Therapeutics's FCF Yield %

For the Biotechnology subindustry, Omega Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omega Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's FCF Yield % falls into.

Omega Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Omega Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-94.379	/	165.98645
	=	-56.86%

Omega Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-12.34	*	4	/	201.31575
	=	-24.52%

Omega Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Omega Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Omega Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Omega Therapeutics (Omega Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omega Therapeutics Inc (NAS:OMGA) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.omegatherapeutics.com

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.

Executives

Michelle C Werner	director	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Christian S Schade	director	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Richard A Young	director, 10 percent owner	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Flagship Pioneering Special Opportunities Fund Ii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Rainer J. Boehm	director	C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
Joshua Reed	officer: Chief Financial Officer	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Kevin Mcmanus	officer: Chief Human Resources Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Ling Zeng	officer: See Remarks	C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON MA 02421
Yan Moore	officer: Chief Medical Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
David A Berry	director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Roger Sawhney	officer: Chief Financial Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Flagship Pioneering Fund Vi General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142